Acute Pain

Latest

Second Complete Response Letter Issued for IV Meloxicam

By

Steve Duffy Digital Content Editor

The Food and Drug Administration (FDA) has sent a second Complete Response Letter to Recro Pharma concerning their New Drug Application for intravenous meloxicam.

Four-to-Seven-Day Opioid Prescription Likely Sufficient for Acute Pain Treatment

An opioid supply for seven or fewer days might be sufficient for most patients seen in primary care settings for acute pain who appear to need opioid analgesics.

Authorized Generic of Flector Patch Now Available From Teva

By

Diana Ernst, RPh

An authorized generic of Flector Patch (diclofenac epolamine topical patch) has been made available by Teva Pharmaceuticals for the topical treatment of acute pain due to minor strains, sprains, and contusions.

New Drug Combination May Be An Effective Prophylactic for Opioid-Induced Nausea

By

Brandon May

CL-108, a new combination of a low-dose antiemetic with hydrocodone and acetaminophen, may be a safe and effective prophylactic medication for the treatment of opioid-induced nausea and vomiting in individuals treated for moderate to severe acute pain.

Methylprednisolone May Provide Short-Term Relief From Acute Diskogenic Sciatica

By

Brandon May

Intravenous administration of methylprednisolone may be associated with short-term pain relief in patients with acute diskogenic sciatica.

Use of Neuraxial Analgesia Varies by State

By

Brandon May

Use of neuraxial analgesia for labor varies across US states, but the causes underlying those variations are unclear.

Sufentanil Sublingual Tablet Well-Tolerated, According to Pooled Safety Data

By

Da Hee Han, PharmD

The pooled analysis (N=804) evaluated clinical studies of sufentanil sublingual tablet (SST) at 30mcg dose equivalents over ≤72 hours for moderate-to-severe acute pain management in both postoperative and emergency room patients.

FDA Approves Two New Strengths of Apadaz for Pain Management

By

Da Hee Han, PharmD

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Postpartum Pain Associated With Increased Risk for Postpartum Depression

By

Abigail Nover

Patients at high risk for postpartum depression may need denser analgesia control after delivery.

Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain

By

Da Hee Han, PharmD

Researchers at the National Institute of Environmental Health Sciences (NIEHS), Vanderbilt University Medical Center, and the Henry Ford Health System analyzed patient data from African-American women aged 23 to 35 years (N=1553) who were participating in the NIEHS Study of Environment, Lifestyle, and Fibroids (SELF).